These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 22959049)

  • 1. Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.
    Yates DR; Brausi MA; Catto JW; Dalbagni G; Rouprêt M; Shariat SF; Sylvester RJ; Witjes JA; Zlotta AR; Palou-Redorta J
    Eur Urol; 2012 Dec; 62(6):1088-96. PubMed ID: 22959049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure of Bacillus Calmette-Guérin therapy in non-muscle-invasive bladder cancer: Definition and treatment options.
    Gual Frau J; Palou J; Rodríguez O; Parada R; Breda A; Villavicencio H
    Arch Esp Urol; 2016 Sep; 69(7):423-33. PubMed ID: 27617552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
    Lamm D; Brausi M; O'Donnell MA; Witjes JA
    Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer.
    Gontero P; Bohle A; Malmstrom PU; O'Donnell MA; Oderda M; Sylvester R; Witjes F
    Eur Urol; 2010 Mar; 57(3):410-29. PubMed ID: 19969411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
    Turker P; Turkeri L
    Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of Bacillus Calmette-Guérin failure classification in non-muscle-invasive bladder cancer.
    Shirakawa H; Kikuchi E; Tanaka N; Matsumoto K; Miyajima A; Nakamura S; Oya M
    BJU Int; 2012 Sep; 110(6 Pt B):E216-21. PubMed ID: 22313616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
    Gandhi NM; Morales A; Lamm DL
    BJU Int; 2013 Aug; 112(3):288-97. PubMed ID: 23517232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
    Malmström PU; Sylvester RJ; Crawford DE; Friedrich M; Krege S; Rintala E; Solsona E; Di Stasi SM; Witjes JA
    Eur Urol; 2009 Aug; 56(2):247-56. PubMed ID: 19409692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
    J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer.
    Sylvester RJ
    Int J Urol; 2011 Feb; 18(2):113-20. PubMed ID: 21091799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developments in intravesical therapy for non-muscle-invasive bladder cancer.
    Lammers RJ; Witjes JA
    Expert Rev Anticancer Ther; 2010 Dec; 10(12):1903-16. PubMed ID: 21110757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
    Kim JC; Steinberg GD
    J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG.
    Barlow LJ; Seager CM; Benson MC; McKiernan JM
    Urol Oncol; 2010; 28(1):108-11. PubMed ID: 20123359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results.
    Witjes JA; Hendricksen K
    Eur Urol; 2008 Jan; 53(1):45-52. PubMed ID: 17719169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Systematic review on conservative treatment options in non-muscle-invasive bladder cancer patients refractory to Bacillus Calmette-Guérin instillation therapy].
    Martini T; Wezel F; Löbig N; Mitterberger MJ; Colleselli D
    Aktuelle Urol; 2017 Aug; 48(4):314-328. PubMed ID: 28609792
    [No Abstract]   [Full Text] [Related]  

  • 20. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
    Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
    BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.